Tegoprazan for functional dyspepsia: A multicenter trial on efficacy and safety

Tegoprazan (50 mg), a potassium-competitive acid blocker, is effective and safe for treating functional dyspepsia, offering prominent symptom relief.

Acid-suppressive drugs like proton pump inhibitors (PPIs) have been commonly used for functional dyspepsia (FD), but the effectiveness of potassium-competitive acid blockers (P-CABs) like Tegoprazan in treating FD is unclear. Hence, this prospective, multicenter, single-arm study aimed to evaluate Tegoprazan’s efficacy and safety for FD patients.

FD-diagnosed participants were tackled with Tegoprazan 50 mg daily for eight weeks. Symptom relief was measured utilizing a dyspepsia symptom questionnaire (Nepean Dyspepsia Index-Korean [NDI-K], gastroesophageal reflux disease–health-related quality of life [GERD-HRQL], 5-point Likert scale). The main goal was to assess relief rates at 8 weeks.

Out of 209 screened patients, 173 completed the study. Symptom alleviation rates were 86.7% at 8 weeks and 74.6% at 4 weeks. Remarkable improvements were seen in NDI-K and GERD-HRQL scores. Tegoprazan's effectiveness was consistent regardless of FD subtype or Helicobacter pylori (H. pylori) status. Patients with overlapping FD and GERD experienced greater improvements. No severe adverse events were reported.

Tegoprazan (50 mg daily) effectively relieved symptoms of functional dyspepsia, demonstrating safety and substantial improvements in the quality of life of the affected patients.